Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicenter study

Clinical Infectious Diseases

Volumn 37, Issue 6, 2003, Pages 800-804

  Sundar, Shyam ^a,f   Jha, T K ^b   Thakur, C P ^c   Mishra, M ^d   Singh, V P ^a   Buffels, R ^e  

^a BANARAS HINDU UNIVERSITY   (India)

^b Kala azar Research Center   (India)

^c Balaji Utthan Sansthan   (India)

^d Kala azar Research Center   (India)

^e Gilead Sciences   (France)

^f NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY GLUCONATE; MILTEFOSINE;

ADOLESCENT; ADULT; ARTICLE; BACKACHE; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEALTH CENTER; HOSPITAL DISCHARGE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARASITOLOGY; PRIORITY JOURNAL; RELAPSE; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; VOMITING;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHILD; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; MIDDLE AGED; PHOSPHATIDYLGLYCEROLS; TREATMENT OUTCOME;

EID: 0141788123     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377542     Document Type: Article

References (23)

1. Berman JD. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24:684-703.
2. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7.
3. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239-43.
4. Mishra M, Singh MP, Choudhury D, Singh VP, Khan AP. Amphotericin B for second line treatment of Indian kala-azar (letter). Lancet 1991; 337:926.
5. Sundar S, Jha TK, Thakur CP, et al. Phase III trial of oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
6. Sundar S. Leishmania and the leishmaniases: treatment of visceral leishmaniasis. Med Microbiol Immunol 2001; 190:89-92.
7. Davidson RN, di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87:75-81.
8. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90:319-20.
9. Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with liposomal amphotericin B lipid complex. J Infect Dis 1996; 173:762-5.
10. Sundar S, Agrawal NK, Sinha PR, Horwith G, Murray HW. Cure with short-course, low dose amphotericin B lipid complex therapy for antimony-unresponsive visceral leishmaniasis. Ann Intern Med 1997; 127:133-7.
11. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Low dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66:143-6.
12. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusion of low dose liposomal amphotericin B: randomized trial. BMJ 2001; 323:419-22.
13. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32:475-9.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guideline for good clinical practice. Available at: http://www.ich.org/ich5e.html. Accessed 25 August 2003.
15. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85:1138-48.
16. Jha SN, Singh NKP, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonials. J Assoc Physicians India 1991; 39:314-16.
17. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
18. Sundar S, Thakur BB, Tandon AK, et al. Clinico-epidemiological study of drug resistance in Indian kala-azar. BMJ 1994; 308:307.
19. Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Ultra-short-course amphotericin B lipid complex treatment for antimony-unresponsive Indian visceral leishmaniasis. Ann Trop Med Parasitol 1998; 92:755-64.
20. Sundar S. Drug Resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-54.
21. Berman JD. U.S. Food and Drug administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:49-51.
22. Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22:938-43.
23. Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995; 21:188-93.